Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation
NCT05950971 · Seoul National University Hospital · NA · terminated · last registry update 2023-07-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study enrollment too slow, 1 over 6 months” | – | Registry record, Seoul National University Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KCNH2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-05Phase 3 first posted: Rush University Medical Center, Chlorhexidine + Gentamicin (NCT06489431)
- 2024-06-11Phase 3 first posted: Amsterdam UMC, Metformin Hydrochloride + Placebo (NCT06452498)
- 2024-05-08Phase 3 first posted: Beni-Suef University, Metformin + Dapagliflozin (NCT06405178)
- 2024-05-01Results posted on the registry: Massachusetts General Hospital, Glipizide + Metformin (NCT01762046)
- 2024-01-30Phase 3 first posted: Mostafa Bahaa, Celecoxib 200mg + Metformin (NCT06231758)
- 2023-11-18Phase 3 first posted: MGH Institute of Health Professions, Dalfampridine 10 MG [Ampyra] (NCT06136728)
- 2023-11-02Phase 3 first posted: University of Utah, a drug against KCNH2 (NCT06112990)
- 2023-10-10Results posted on the registry: Janssen Research & Development, LLC, Erdafitinib + Midazolam (NCT02365597)
- 2023-09-13Phase 3 first posted: Lina Bergman, Metformin ER + Placebo (NCT06033131)
- 2023-07-28Phase 3 first posted: Beni-Suef University, liraglutide + Metformin (NCT05965908)
- 2023-07-13Results posted on the registry: University of Minnesota, Metformin + Placebo (NCT04510194)
- 2023-05-03Phase 3 first posted: Population Health Research Institute, Amiodarone Hydrochloride 200 MG (NCT05841056)
- 2023-02-01Phase 3 first posted: Future University in Egypt, Metformin (NCT05708053)
- 2022-11-01Phase 3 first posted: Beni-Suef University, Dapagliflozin 5 MG + Metformin Hydrochloride 1000 MG (NCT05601336)
- 2022-07-21Phase 3 first posted: Medical University of Bialystok, metformin (NCT05468554)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision